Citizens JMP Sticks to Their Buy Rating for ProQR (PRQR)
Citizens JMP analyst Jonathan Wolleben reiterated a Buy rating on ProQR today and set a price target of $8.00. The company’s shares closed yesterday at $2.46.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Wolleben covers the Healthcare sector, focusing on stocks such as Larimar Therapeutics, Quince Therapeutics, and Rhythm Pharmaceuticals. According to TipRanks, Wolleben has an average return of 15.7% and a 51.10% success rate on recommended stocks.
ProQR has an analyst consensus of Strong Buy, with a price target consensus of $8.25.
PRQR market cap is currently $240.9M and has a P/E ratio of -5.54.
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.